tradmap

ALEC Alector, Inc.

$2.50 -8.09%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Alector, Inc. (ALEC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $279 million. Shares last traded at $2.50, 26.4% below their 52-week high. Over the past year the stock is down 10.7%. Net profit margin is -850.1%, below the peer median of 5.3%. Revenue declined 79.1% year over year.

Market Cap
$279M
Shares Out
111.7M
EPS (TTM)
$-2.38
P/E Ratio
P/S Ratio
20.14
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$3.40
52-Week Low
$1.09
Volume
313,424
Avg Vol (3m)
70,856.635

Performance

1W
+4.60%
1M
+68.92%
3M
+38.12%
6M
+25.00%
YTD
+64.47%
1Y
-10.71%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
60.38
SMA (50)
$1.89
SMA (200)
$1.92
Price vs SMA50
+32.48%
Price vs SMA200
+30.43%
ATR (14)
$0.20

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$14M
Net Income
$-118M
Gross Margin
Operating Margin
-912.4%
Net Margin
-850.1%
Return on Equity
1182.1%
Return on Assets
-58.1%
Current Ratio
5.26
Debt / Equity
0.00
Revenue Growth (YoY)
-79.1%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.41 2026-08-06
Q1 2026 $-0.21 2026-05-07
FY 2025 $-1.39 2026-02-25
Q3 2025 $-1.05 2025-11-06
Q2 2026 $-0.71 2026-08-06
Q1 2026 $-0.41 2026-05-07

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ALEC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
20.14 / 19.49 med
+3% premium
Net margin vs peers
-850.1% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.